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Abstract
Aims To investigate the consequences of oxidative stress
and hypoxia on EPAC-1 expression during retinopathy.
Methods Oxygen-induced retinopathy was induced in mice
and EPAC-1 expression investigated by immunofluores-
cence. In silico analyses were used to identify a link
between EPAC-1 expression and microRNA-7-5p in
endothelial cells and confirmed by western blot analyses on
cells expressing microRNA-7-5p. In vitro, endothelial cells
were either incubated at 2% oxygen or transfected with
microRNA-7-5p, and the effects of these treatments on
EPAC-1 expression, endothelial hyperpermeability and NO
production were assessed. In the Ins2Akita mouse model,
levels of EPAC-1 expression as well as microRNA-7-5p
were assessed by qPCR. Endothelial nitric oxide synthase
was assessed by immunoblotting in the Ins2Akita model.
Results Hypoxia induces the expression of microRNA-7-
5p that translationally inhibits the expression of EPAC-1 in
endothelial cells, resulting in hyperpermeability and the
loss of eNOS activity. Activation of EPAC-1 by the cAMP
analogue 8-pCPT-20-O-Me-cAMP reduced the sensitivity
of EPAC-1 to oxidative stress and restored the endothelial
permeability to baseline levels. Additionally, 8-pCPT-20-
O-Me-cAMP rescued eNOS activity and NO production. In
mouse models of retinopathy, i.e., oxygen-induced
retinopathy and the spontaneous diabetic heterozygous
Ins2Akita mice, EPAC-1 levels are decreased which is
associated with an increase in microRNA-7-5p expression
and reduced eNOS activity.
Conclusion/Interpretation In retinopathy, EPAC-1
expression is decreased in a microRNA-7-mediated man-
ner, contributing to endothelial dysfunction. Pharmaco-
logical activation of remnant EPAC-1 rescues endothelial
function. Collectively, these data indicate that EPAC-1
resembles an efficacious and druggable target molecule for
the amelioration of (diabetic) retinopathy.
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Introduction
The vascular endothelium exhibits multiple structural and
functional abnormalities in response to hypoxia that may
contribute to the pathogenesis of several vascular diseases,
including (diabetic) retinopathy [1]. Hypoxia is associated
with an increment in oxidative stress [2] and the disruption
of endothelial adhesion molecules [3, 4], resulting in
increased endothelial permeability [5] and impairment of
vasodilation [6, 7].
30,50-Cyclic adenosine monophosphate (cAMP) is an
ubiquitous second messenger that activates two down-
stream signaling cascades, i.e., protein kinase A (PKA) and
the more recently discovered exchange protein activated by
cAMP (EPAC) [8, 9]. In endothelial cells, EPAC signaling
enhances the barrier function by promoting VE-cadherin
junctional stability, thereby reducing endothelial perme-
ability [10, 11]. Corroboratively, Epac1 activation by
cAMP or the cAMP analogue 8-pCPT reverses endothelial
hyperpermeability induced by inflammatory mediators
[12, 13]. Next to the regulatory effects on the endothelial
barrier, EPAC participates in the cAMP-induced vascular
relaxation in arteries [14, 15], in part by activating
endothelial nitric oxide synthase (eNOS) [16, 17]. Con-
curringly, EPAC expression is dysregulated in pathologies
that are characterized by endothelial dysfunction and
edema formation [18–20].
Although the downstream consequences of EPAC activa-
tion on endothelial function receive increasing attention [20],
factors regulating the expression of EPAC during pathology
remain elusive. In retinopathy hypoxia might contribute to
EPAC dysregulation. We recently uncovered that EPAC-1 is
targeted bymicroRNA-7 in human pulmonary smoothmuscle
cells, and microRNA-7 expression is associated with
increased oxidative stress levels [21]. Therefore, we hypoth-
esized that microRNA-7 might induce EPAC-1 deregulation
during retinal hypoxia or in diabetic conditions.
Here, we describe that EPAC-1 expression is inhibited
by hypoxia in vivo in the oxygen-induced retinopathy
mouse model [22, 23] and in endothelial cell cultures
exposed to hypoxia. Furthermore, we show that the
reduction in EPAC-1 expression is associated with the
hypoxia-induced expression of microRNA-7, resulting in
translational repression. Activation of the remnant EPAC-1
in endothelial cells counteracts hypoxia-induced endothe-
lial hyperpermeability and reverses the NO/ROS imbalance
through eNOS activation. Moreover, in the Ins2Akita mouse
model for diabetic retinopathy (DR), EPAC-1 expression is
vastly reduced, which coincides with a marked increase in
microRNA-7 expression. These data indicate that EPAC-1
is a pivotal regulator of endothelial function in (diabetic)
microangiopathies involving endothelial dysfunction asso-
ciated with hypoxia, and might serve as promising thera-
peutic targets to ameliorate these conditions.
Animals, materials and methods
Animals and ethical approval
C57BL/6J mice and spontaneous diabetic heterozygous
Ins2Akita?/- mice (Jackson Laboratory, Charles River,
Sulzfeld, Germany) were used throughout the study. Age-
matched non-diabetic homozygous Ins2Akita-/- mice
served as control. All experimental procedures were per-
formed according to the guidelines of the statement for
animal experimentation issued by the Association for
Research in Vision and Opthalmology and were approved
by the local board for animal care (Medical Faculty Man-
nheim, Germany).
Oxygen-induced retinopathy mouse model
Oxygen-induced retinopathy was induced in C57BL/6J
mice as described previously [22, 23]. In short, newborn
mice (n = 6) at postnatal day (p) 7 were exposed to
hyperoxia (75% oxygen) in an incubation chamber (Stuart
Scientific, Redhill, UK) with their nursing mothers for
5 days and then returned to ambient air, creating a relative
hypoxic environment. Control mice (n = 6) were kept at
ambient air and used as a control group. Mice were killed
at p12 (i.e., 6 h of relative hypoxia) and p13 (i.e., 24 h of
relative hypoxia), and the retinas were isolated as described
previously [23].
Retinopathy in Ins2Akita mice
After 6 months of diabetes, mice (n = 6/group) were killed
and the retinas were isolated as described previously [23].
Human endothelial cell culture
Human umbilical vein endothelial cells (Lonza, Breda, the
Netherlands) were cultured in endothelial growth medium,
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consisting of RPMI 1640, L-glutamine (2 mM), penicillin/
streptomycin (1%; all Lonza, Breda, the Netherlands),
bovine pituitary extract (20 lg/ml; Invitrogen/Life Tech-
nologies, Bleiswijk, The Netherlands), heparin (5 U/ml;
Leo Pharma, Amsterdam, The Netherlands), and FBS
(20%; Thermo Scientific, Waltham, MA).
When appropriate, confluent endothelial cell cultures were
serum starved for 24 h, and cells were treated with fenoterol
(1 lM; Boehringer Ingelheim, Germany), forskolin (10 lM;
Tocris, UK), 6-Bnz-cAMP (300 lM), 8-pCPT-20-O-Me-
cAMP (100 lM) (Biolog Life Science Institute, Germany), or
ESI-09 (5 lM, SelleckChem, Germany).
Parallel cultures were maintained under normoxic (21%
oxygen tension) and hypoxic conditions (2% oxygen ten-
sion) for 48 h prior to experiments. To establish hypoxia, cell
culture medium was deoxygenated by bubbling gaseous N2
through the medium at room temperature for 30 min. Cells
were maintained in an hypoxic cell culture incubator at
37 C containing 2% O2, 93% N2, and 5% CO2.
Construction of 30UTR reporter constructs and micro-
RNA-7-5p transfection in COS7 and Endothelial cells. The
30UTR fragments of EPAC-1 and EPAC-2 were isolated by
conventional PCR amplification. 50 SgfI- and 30 NotI
restriction sites (underlined) were incorporated in the pri-
mer sequences; EPAC-1 sense: 50-CCGCCGGCGATCGC
AGGAGTGGGTGGAGAGTGGA-30 and antisense: 50-CA
TGCGGCCGCGTGTCCCCACCCACGGCAAG-30 and
EPAC-2 sense: 50-ATATATGCGATCGCACATTTCAAA
TGCCCAAAGC-30 and antisense: 50-GCAGCGGCCGCA
TTGAATGAACTATTTACAA-30. Amplicons were iso-
lated using the QIAquick Gel Extraction Kit (Qiagen Inc)
according to manufacturer’s instructions, modified using
SfgI and NotI restriction enzymes (Fermentas) and inserted
in the psiCHECK-2 vector (Promega) using T4 ligase.
MicroRNA-7 mimics and scrambled sequences were
obtained from ThermoFisher Scientific and co-transfected
with 30UTR reporter constructs into COS-7 cells using
EndoFectin (GeneCopoeia, Rockville, MD). Co-transfec-
tion of miR-7 mimics and an 30UTR-free psiCHECK-2
plasmid were used as controls.
Endothelial cells were transfected using microRNA-7
mimics and scrambled sequences using EndoFectin (Gen-
eCopoeia, Rockville, MD).
Endothelial permeability assays
Endothelial cells (1.0 9 105/cm2) were cultured on poly-
carbonate cell culture inserts (pore size 0.4 lm, porosity
0.9108/cm2; Nunc, ThermoFisher, Waltham, CA) coated
with 0.1% gelatin for 48 h. When appropriate, cultures
were serum starved for 24 h and cells were treated with
fenoterol (1 lM; Boehringer Ingelheim, Germany), for-
skolin (10 lM; Tocris, UK), 6-Bnz-cAMP (300 lM) or
8-pCPT-20-O-Me-cAMP (100 lM) (Biolog Life Science
Institute, Germany). Parallel cultures were maintained
under normoxic (21% oxygen tension) and hypoxic con-
ditions (2% oxygen tension) for 48 h prior to experiments.
Permeability was assessed by the addition of 10 lg/ml
FITC-dextran in the upper compartments, and fluorescence
in the lower compartments was assessed on a spectrofluo-
rescence reader at Ex485/Em519 after 30 min.
Immunofluorescence
Endothelial cells were cultured in eight-well Lab-Tek
chamber slides (Nunc, IL, USA) until 80% confluence was
reached. Cells were incubated under normoxic or hypoxic
conditions for 24 h. Samples were fixed in 2%
paraformaldehyde in PBS for 20 min and permeabilized
with 0.3% Triton X-100 for 10 min. Blocking of unspecific
antibody activity was performed using in 2% BSA. Sam-
ples were incubated with rabbit polyclonal antibodies to
human EPAC-1 (Abcam, #ab21236, 1:100) and eNOS (BD
#61098, 1:200) diluted in 2%BSA/PBS overnight at 4 C.
Samples were washed and incubated with Alexa Fluor
594-conjugated goat anti-rabbit IgG antibodies (Molecular
Probes, Invitrogen, OR, USA) diluted 1:500 in DAPI/PBS
for 1 h at room temperature. Samples were mounted in
Citifluor AF1 (Agar Scientific, UK), and cells were
examined using a Leica TCS SP8 (Leica Microsystems,
Germany) laser scanning fluorescence confocal microscope
using a 63x/1.40 oil objective.
Gene and microRNA transcript analysis
Total RNA was isolated using TRIzol reagent (Invitrogen,
Waltham, CA) according to manufacturer’s instructions
and quantified by spectrophotometry (NanoDrop Tech-
nologies, Waltham, MA). For gene expression analyses,
1 lg of total RNA was reversely transcribed into cDNA
using the RevertAidTM First-Strand cDNA synthesis kit
(Applied Biosystems, Carlsbad, CA) and amplified using
species-specific primers (human primers: Suppl. Table 1;
mouse primers Suppl. Table 3). For microRNA expression
analyses, 20 ng total RNA was reversely transcribed using
the TaqMan MicroRNA Reverse Transcription kit (Applied
Biosystems) using specific stemloop templates for miRNA-
7-5p (50-GTCGTATCCAGTGCAGGGTCCGAGGTATT
CGCACTGGATACGACACAACAAA-30) or RNU6 (50-G
TCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG
GATACGACAAAAATATGG-30) and amplified using
sense 50-TGCGGTTGGAAGACTAGTGAT-30, antisense
50-CCAGTGCAGGGTCCGAGGTCCG-30 for miR-7-5p,
and sense 50-TGCGGCTGCGCAAGGATGA-30, antisense
50-CCAGTGCAGGGTCCGAGGTCCG-30 for RNU6.
Quantitative PCR expression analysis was performed on a
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reaction mixture containing 10 ng cDNA equivalent,
0.5 lM sense primers, and 0.5 lM antisense primers (all
Biolegio, Leiden, The Netherlands) and FastStart SYBR
Green (Roche, Almere, The Netherlands). Analyses were
run on a Viia7 real-time PCR system (Applied Biosystems,
Carlsbad, CA). Each reaction was performed in triplicate
and gene expression was calculated using the DDCt
method. The data are expressed as fold change versus
control.
Protein analysis
Retinal digests and endothelial cells were lysed in RIPA
buffer (ThermoScientific, Waltham, MA) and protein con-
centration determined by DC Protein Assays (BioRad,
Hercules, CA) according to manufacturers’ instructions.
30 lg of protein/lane was loaded on a SDS-PAGE gel
(8–12%) for electrophoresis and transferred to a nitrocellu-
lose membrane. Membranes were incubated overnight with
antibodies to EPAC-1 (Abcam, Cambridge, UK, #ab21236,
1:1000), VE-Cadherin (Cell Signaling, #2500, 1:1000),
eNOS (BD, San Jose, CA, #61098, 1:2000), phopho-Ser1177
eNOS (BD, San Jose, CA, #612393, 1:1000), and b-actin
(Cell Signaling, #4967, 1:5000) for 1 h at RT. IRDye-la-
beled antibodies (1:10.000, Li-COR Biosciences, Lincoln,
NE)were used for detection. Bandswere visualized using the
Odissey Infrared Imaging System (Li-COR Biosciences,
NE, USA). Densitometry was performed using Image J
version 1.45 s (NIH, Bethesda, MD). Protein expression
levels were normalized to b-actin.
Nitrite and ROS measurements
Nitrite levels in the cell culture medium, a stabile indicator
of NO production, were quantified using the Measure-iTTM
High-Sensitivity Nitrite Assay Kit (Molecular Probes,
Eugene, OR) according to the manufacturer’s protocol.
Obtained nitrite concentrations were normalized against
the total amount of cellular protein using the DC protein.
Reactive oxygen levels were determined by incubating
the cells with 50 lM 20,70-dichlorofluorescin diacetate
(DCFH-DA, Sigma-Aldrich, St. Louis, MO) for 10 min in
dark. Cells were dissociated using AccutaseTM solution
(PAA Laboratories, Austria), pelleted by centrifugation,
and suspended in PBS. The generation of intracellular ROS
was determined by flow cytometry on the FACSCalibur
and WinList version 6.0 software (both BD Biosciences,
CA, USA).
MicroRNA in situ hybridization
Double DIG-labeled MicroRNA-7-5p and scrambled con-
trol probes, microRNA ISH buffers, and reagents were
obtained Exiqon (Vedbaek, Denmark) and used according
to the manufacturers’ protocol. Hybridization was per-
formed for 16 h at 44 C in a humidified chamber.
Data presentation and statistical analysis
Data is expressed as mean ± SEM. Significant differences
between two means were determined by Mann–Whitney
two-tailed U test for unpaired data or by one-way analysis
of variance (ANOVA) followed by Dunnett’s post hoc test,
where appropriate. p values\0.05 were considered statis-
tically significant.
Results
Hypoxia decreases EPAC-1 expression
Oxygen-induced retinopathy is associated with a marked
decrease in EPAC-1 expression (Fig. 1a). After 6 h and
24 h of relative hypoxia, retinal EPAC-1 gene transcript
levels were reduced (2.0- and 1.9-fold, respectively,
p\ 0.05, Fig. 1b Conversely, miR-7 expression was
increased in the retina of OIR-mice (2.7- and 3.2-fold,
p\ 0.01) compared to normoxic control mice (Fig. 1c).
The effect of hypoxia on EPAC-1 expression was con-
firmed in endothelial cell cultures exposed to 2% (hy-
poxia) or 20% (normoxia) oxygen, where EPAC-1
protein expression decreased (2.4-fold, p\ 0.01, Fig. 1d,
e) when cells were exposed to hypoxia for 24 h. These
data indicate that the expression of EPAC-1 is oxygen
sensitive and its expression is decreased during hypoxic
stress.
Hypoxia induces microRNA-7-mediated suppression
of EPAC-1
Endothelial cells exposed to 2% oxygen for 24 h increased
miR-7 expression by 9.1-fold (p\ 0.01, Fig. 2a). Micro-
RNA-7 contains a seed sequence that has complementarity
to the 30Untranslated Region (UTR) of EPAC-1 and EPAC-
2. EPAC-1 has five putative miR-7 binding sites, whereas
EPAC-2 only has one putative miR-7 binding site
(Fig. 2b). To confirm that EPAC-1 and EPAC-2 are gen-
uine targets of miR-7, we produced reporter constructs
wherein the expression of luciferase is under the control of
the 30UTR of EPAC-1 or EPAC-2. Co-transfection of
COS7 cells with miR-7 mimics and the EPAC-1 reporter
construct decreased luciferase activity (2.6-fold) compared
to scrambled controls (p\ 0.05), whereas the luciferase
activity of the EPAC-2 reporter was unaffected (Fig. 2c).
These data indicate that EPAC-1 is a specific target of miR-
7. Corroboratively, in endothelial cells transfected with
Acta Diabetol
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miR-7 mimics EPAC-1 protein expression was decreased
2.1-fold (p\ 0.05, Fig. 2d).
cAMP signaling counteracts hypoxia-induced
endothelial hyperpermeability
Hypoxia causes endothelial hyperpermeability (Fig. 3a),
which associates with only a minor decrease (1.2-fold,
p\ 0.01) in VE-cadherin expression (Fig. 3b). Stimula-
tion of endothelial cells with the adenylyl cyclase acti-
vator forskolin (10 lM) significantly reduced the hypoxia-
induced endothelial hyperpermeability (2.2-fold,
p\ 0.001, Fig. 3c). Similarly, the administration of the
selective protein kinase A (PKA) agonist (6-Bnz-cAMP,
300 lM) and EPAC agonist (8-pCPT-20-O-Me-cAMP,
100 lM), two downstream mediators of adenylyl cyclase
activity, inhibited hypoxia-induced endothelial
hyperpermeability [1.6-fold (p\ 0.01) and 2.1-fold
(p\ 0.001), respectively] (Fig. 3c). Interestingly, treat-
ment of endothelial cells with ESI-09, an antagonist to
EPAC-1, induced endothelial hyperpermeability under
normoxic conditions (Fig. 3d). Conversely, a b2-agonist,
fenoterol (1 lM) did not reduce endothelial hyperperme-
ability (Fig. 3c). Also, none of the treatments altered
endothelial permeability under normoxic conditions (not
shown).
We next investigated if the addition of miR-7 mimics to
endothelial cells would imitate the hypoxia-induced
endothelial hyperpermeability. Indeed, supplementing
endothelial cells with miR-7 mimics induced hyperper-
meability (Fig. 3e) in the absence of hypoxia and without
alterations to VE-cadherin expression (Fig. 3f). Remark-
ably, treating miR-7-expressing cells with 8-pCPT reduced
endothelial hyperpermeability (1.7-fold, p\ 0.05),
Fig. 1 Hypoxia decreases EPAC-1 expression. a Immunofluores-
cence analysis and b gene expression analysis for Epac-1 following
relative hypoxia in vivo for 6 and 24 h. Hypoxia decreases EPAC-1 in
the oxygen-induced retinopathy model. Conversely, c hypoxia
increases retinal microRNA-7-5p expression at 6 and 24 h.
d Immunofluorescence analysis and e western blot analysis for
EPAC-1 in vitro. Long-term (24 h) hypoxia decreases EPAC-1
expression in cultured endothelial cells. Cntr = unstimulated
endothelial cells; *p\ 0.05; **p\ 0.01. Data are expressed as
mean ± SEM of at least three independent experiments
Fig. 2 Hypoxia induces microRNA-7-mediated suppression of
EPAC-1. a Hypoxia induces the expression of miR-7 by endothelial
cells. b In silico analysis of the 30UTR of EPAC-1 and EPAC-2.
EPAC-1 has 5 putative miR-7 binding sites, whereas EPAC-2 has one
putative miR-7 binding site. c Luciferase reporter assays for miR-
7:30UTR binding for EPAC-1 and EPAC-2. EPAC-1 is a genuine
target of miR-7. d Immunoblotting of EPAC-1 in endothelial cells
transfected with miR-7 mimics or scrambled sequences. MiR-7
mimics decrease EPAC-1 protein expression in cultured endothelial
cells. Cntr control (30UTR reporter only), scr scrambled sequence




indicating that activation of remnant EPAC-1 is sufficient
to inhibit miR-7-induced endothelial hyperpermeability.
cAMP signaling counteracts hypoxia-induced
endothelial oxidative stress
Endothelial NOS protein expression by cells exposed to
hypoxia was reduced *40% (p\ 0.05, Fig. 4a, b) com-
pared to normoxic controls, which resulted in decreased
NO production (1.4-fold, p\ 0.05, Fig. 4c) and the
increased generation of reactive oxygen species (ROS)
(1.6-fold, p\ 0.01, Fig. 4d).
The addition of miR-7 mimics to endothelial cells did
not cause a reduction in eNOS expression level (Fig. 4e).
However, the addition of miR-7 mimics to endothelial cells
did imitate the hypoxia-induced loss of eNOS activity as
indicated by a reduction in eNOS phosphorylation at serine
1177 (p-eNOS/eNOS ratio; 1.7-fold decrease, p\ 0.01;
Fig. 4e).
Fenoterol (1 lM) tended to increase eNOS phosphory-
lation at serine 1177 (p-eNOS/eNOS ratio) in endothelial
cells exposed to hypoxia (Fig. 4f), whereas forskolin
(10 lM), 6-Bnz-cAMP (300 lM) and 8-pCPT-20-O-Me-
cAMP (100 lM) efficiently increased eNOS activation by
2.3, 2.8 and 2.2-fold respectively (all p\ 0.05, Fig. 4f).
Corroboratively, NO production in hypoxia-treated
endothelial cells was increased (1.4- to 1.6-fold) by these
activators of cAMP signaling (Fig. 4g), and ROS produc-
tion was decreased to a similar extend (Fig. 4h).
EPAC-1 and microRNA-7 alterations in diabetic
retinopathy
In the Ins2Akita model for diabetic retinopathy (Table 1),
retinal EPAC-1 levels were reduced (*5.7-fold, p\ 0.01)
compared to non-diabetic control mice (Fig. 5a), whereas
gene expression levels of EPAC-2 remained unchanged
(Fig. 5b). MiR-7-5p was detected by in situ hybridization
in the retinae from diabetic Ins2Akita mice (Fig. 5c),
where its expression of miR-7 was increased (3.2-fold,
p\ 0.01, Fig. 5d) compared to non-diabetic controls. In
control C57BL/6 mice, miR-7-5p levels remained below
the detection limit for in situ hybridization (Fig. 5c).
EPAC-1 expression levels associated with miR-7-5p
Fig. 3 cAMP signaling counteracts hypoxia-induced endothelial
hyperpermeability. a Permeability of endothelial monolayers grown
under normoxic and hypoxic conditions. Hypoxia increases endothe-
lial permeability. b Immunoblotting for VE-cadherin in endothelial
cells grown under normoxic or hypoxic conditions. c Permeability of
endothelial monolayers grown under hypoxia and stimulated with
fenoterol (1 lM; FEN), forskolin (10 lM; FSK) or the cAMP
analogues 6-bnz-cAMP (300 lM; PKA activator; Bnz) and 8-pCPT-
20-O-Me-cAMP (100 lM; EPAC-1 activator; pCPT). Stimulation of
cAMP signaling decreases endothelial permeability under hypoxia.
d Permeability of endothelial monolayers stimulated with the EPAC-
1 inhibitor ESI-09 (10 lM) is increased under normoxic conditions.
e miR-7 mimics increase endothelial monolayer permeability under
normoxic conditions without affecting f VE-cadherin expression.
g The miR-7-induced endothelial hyperpermeability is antagonized
by the EPAC-1 activator ESI-09. N normoxia (20% O2), H hypoxia
(2% O2), Scr scrambled sequence control; *p\ 0.05; **p\ 0.01;




expression levels to a high extend (r2 = 0.464, p\ 0.001,
Fig. 5c) indicating that the hypoxia-induced expression of
miR-7 might underlie the loss of EPAC-1 expression in
diabetic retinopathy. In the Ins2Akita mice, endothelial
hyperpermeability, as assessed by leakage of fluorescently
labeled low molecular weight dextran, was not observed
(data not shown). However, eNOS activation decreased
2.4-fold (p\ 0.01, Fig. 5f) compared to control mice,
suggestive of reduced EPAC signaling.
Besides EPAC-1 [21], miR-7 targets a number of
additional gene transcripts (Suppl. Table 1). We analyzed
the expression of 23 reported miR-7-5p target genes in
endothelial cells that express miR-7-5p (Suppl. Table 2)
and in retinal isolations from diabetic Ins2Akita mice
(Suppl. Table 4) and found no other transcript which was
decreased in both conditions.
Discussion
Here, we show that hypoxia induces the expression of miR-
7 by endothelial cells in vitro and in vivo, reducing the
expression of EPAC-1. The hypoxia-induced reduction in
EPAC-1 levels results in endothelial hyperpermeability and
a NO/ROS imbalance and is associated with the develop-
ment of (diabetic) retinopathy. Activation of EPAC-1 by
forskolin or the cAMP analogue 8-pCPT reduces the sen-
sitivity of EPAC-1 to oxidative stress and restores the
endothelial permeability barrier and rescues NO production
by eNOS. These data suggest that EPAC-1 is an appro-
priate drug target for the treatment of endothelial dys-
function during (diabetic) retinopathy.
(Diabetic) Retinopathy is characterized by hypoxia-in-
duced vascular dysfunction, resulting in the degradation of
the blood-retinal barrier (BRB) and concomitant macular
edema formation. Herein, hypoxia induces the loss of
endothelial cell–cell junctions and oxidative stress [24, 25].
Although cAMP signaling is commonly known to regulate
Fig. 4 cAMP signaling counteracts hypoxia-induced endothelial
oxidative stress. a Immunofluorescence analysis of eNOS expression
by endothelial monolayers grown under normoxic and hypoxic
conditions. b Immunoblotting for eNOS in endothelial cells grown
under normoxic or hypoxic conditions. c Nitrite formation (indirect
measurement of NO production) by endothelial cells grown under
hypoxia is reduced, whereas d ROS production is increased. e miR-7
mimics decrease eNOS activity under normoxic conditions without
affecting eNOS expression level. f Endothelial NOS phosphorylation
at Ser 1177 of endothelial monolayers grown under hypoxia and
stimulated with forskolin (10 lM; FSK) or the cAMP analogues
6-bnz-cAMP (300 lM; PKA activator; Bnz) and 8-pCPT-20-O-Me-
cAMP (100 lM; EPAC-1 activator; pCPT). Stimulation of cAMP
signaling increases the phosphorylation of eNOS at Ser1177.
f Increased eNOS phosphorylation coincides with f increased nitrite
formation and g reduced ROS formation. N normoxia (20% O2),
H hypoxia (2% O2); Veh vehicle (DMSO) control, FEN fenoterol
(1 lM); *p\ 0.05; **p\ 0.01; ***p\ 0.001. Data are expressed as
mean ± SEM of at least three independent experiments
Table 1 Metabolic data of Diabetic Ins2Akita mice
C57BL/6 Ins2Akita p value
Age (months) 6 6
Body weight (g) 34.65 ± 3.69 26.24 ± 1.48 \0.0001
Blood glucose (mg/dl) 209 ± 33 [600 \0.0001
HB1Ac (%) 6.38 ± 0.68 13.33 ± 1.03 0.0005
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endothelial permeability and NO production [26, 27], little
is known on the role of cAMP signaling in retinopathy.
Yet, agonist to the b-adrenergic system [28, 29] and taurine
[30] prevent retinal endothelial hyperpermeability in part
through the activation of cAMP signaling.
Considering these antecedents, we investigated cAMP
signaling in the oxygen-induced retinopathy model [22]
and found a marked decrease in the expression of the
cAMP signaling intermediate EPAC-1. Concurrently,
exposing endothelial cells to a hypoxia challenge in vitro
similarly reduced EPAC-1 expression levels, suggesting
that the loss of EPAC-1 might contribute to the hypoxia-
induced retinopathy. Indeed, adenosine reduces inflamma-
tory retinopathy by activating EPAC1-1 [31].
We had previously found an association between EPAC-
1 and miR-7 expression levels in airway smooth muscle
cells [21]. MicroRNAs are endogenous translational
repressors of gene expression. Hence, we investigated if
hypoxia could affect EPAC-1 expression through miR-7.
Indeed, hypoxia induced the expression of miR-7 in
endothelial cells and transfection of endothelial cells with
miR-7 mimics reduced EPAC-1 expression by *50%.
The integrity of the BRB is highly dependent on
endothelial adherence junctions that consist of VE-cad-
herin and associated catenins. Hypoxia reduces the pres-
ence of VE-cadherin in the endothelial cell–cell junctions
[32], resulting in endothelial hyperpermeability. This
change in permeability might be derived from the hypoxia-
induced reduction in EPAC-1 expression, as EPAC-1 is
pivotal in maintaining VE-cadherin at the cell–cell junction
through the activation of Rac [10, 26]. Corroboratively,
inhibition of EPAC-1 activity with the small molecule ESI-
09 or miR-7-5p mimics increases the endothelial perme-
ability. Interestingly, hypoxia-mediated endothelial hyper-
permeability was associated with a decreased in VE-
cadherin expression, whereas hyperpermeability induced
by miR-7-5p mimics was not. As both models are char-
acterized by a similar reduction in EPAC-1, these data
suggest that hypoxia-driven hyperpermeability involves at
least one other cascade that results in the degradation of
Fig. 5 EPAC-1 and microRNA-7 alterations in diabetic retinopathy.
a EPAC-1 gene expression in retinal lysates of 6-month-old
spontaneous diabetic heterozygous Ins2Akita?/- and control non-
diabetic littermates (homozygous Ins2Akita-/- mice). b EPAC-1
gene expression in retinal lysates of 6-month-old spontaneous diabetic
heterozygous Ins2Akita?/- and control non-diabetic littermates
(homozygous Ins2Akita-/- mice). c In situ hybridization using
scrambled probes or miR-7-5p-specific probes on retinal digests from
6-month-old spontaneous diabetic heterozygous Ins2Akita?/- and
control non-diabetic littermates. d MicroRNA-7-5p expression in
retinal lysates of spontaneous diabetic Ins2Akita?/- and control mice.
e Association between the EPAC-1 and miRNA-7-5p expression
levels in non-diabetic and diabetic Ins2Akita mice. f Levels of




VE-cadherin. Activation of the remnant EPAC-1 by for-
skolin or the cAMP analogue 8-pCPT antagonizes the
hypoxia or miR-7-induced endothelial hyperpermeability.
These data are corroborated by earlier findings of Aslam
et al. [32], who describe the restoration of VE-cadherin at
the cell–cell junction by 8-pCPT under hypoxic conditions.
As our data implies that miR-7-5p underlies hyperper-
meability in oxygen-induced retinopathy and eNOS
uncoupling in diabetic retinopathy, inhibition of miR-7-5p,
or EPAC-1 activation seem a promising approach to restore
retinopathy. Unfortunately, the current methodology to
assess permeability in vivo, i.e., Evans Blue dye leakage,
or FITC-Dextran leakage, is too insensitive to provide
reproducible results on the relative permeability in
Ins2Akita. The development of novel technologies, such as
scanning laser ophthalmoscopy or optical coherence
tomography [33] may provide better resolution in the near
future. Alternatively, the streptozotocin-induced rat model
for retinopathy, which produced a high retinal hyperper-
meability, could be used to investigate the efficacy of
EPAC activating drugs.
Additionally, it would be of interest to investigate if
EPAC-1 activation can rescue the VEGFa-induced
endothelial hyperpermeability, as this is not only associated
to (diabetic) retinopathy, but also with endothelial hyper-
permeability in tumors.
Besides endothelial hyperpermeability, in retinopathy,
hypoxia contributes to endothelial oxidative stress orches-
trated by eNOS [34]. Here, we found a marked reduction in
eNOS expression and phosphorylation during hypoxia,
which coincided with decreased NO levels and elevated
ROS production. Interestingly, the reduction in eNOS
mRNA stability and eNOS activity are dependent on the
activity of Rho-kinase [35]. It is conceivable that the
hypoxia-induced suppression of EPAC-1 expression and
activity would concomitantly increase Rho-kinase activity,
which would in turn cause the observed reduction in eNOS
expression and activation. Besides, the observed reduction
in eNOS phosphorylation at Ser1177 might result in eNOS
uncoupling and the concomitant generation of ROS.
Indeed, in the present study we observe decreased eNOS
activity under hypoxic conditions, reflected by reduced
nitrite formation, and increased ROS production. More-
over, endothelial cells that were transfected with miR-7-5p
mimics showed decreased eNOS activity and eNOS
activity is decreased in the retinae of diabetic Ins2Akita
mice. Activation of EPAC-1 in endothelial cells that
received a hypoxic challenge using forkolin or 8-pCPT
completely rescued this phenotype and restored NO pro-
duction and inhibited the formation of ROS.
A potential limitation of our study is the use of umbilical
vein endothelial cells, which are macrovascular cells.
Although we cannot fully exclude that retinal
microvasculature endothelial cells would behave different
with respect to miR-7-5p or EPAC-1 stimulation, in pre-
liminary experiments we have found no difference between
the umbilical vein endothelial cells and dermal microvas-
cular endothelial cells (data not shown).
In summary (Fig. 6), here we report that the hypoxia-
induced reduction in EPAC-1 expression and activity
contributes to the generation of retinopathy through the
disruption of the endothelial barrier in the OIR model, or
by eNOS uncoupling (disturbing the NO/ROS balance) in
the Ins2Akita model. The reduction in EPAC-1 expression
is in part due to the hypoxia-induced expression of miR-7.
Pharmacological activation of EPAC-1 by forskolin or
8-pCPT antagonizes the hypoxia-induced endothelial dys-
function. Therefore, EPAC-1 resembles an efficacious and
druggable target molecule for the amelioration of (diabetic)
retinopathy.
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